GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, announced the relocation of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for the fourth quarter of 2025, are intended to support the company's continued growth, expanding pipeline, and preparation for product commercialization.
GeoVax's laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the company's R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities. The new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a hub for corporate operations and leadership activities.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated, 'These moves reflect a significant milestone in GeoVax's evolution. By placing members of our R&D team in one of the most dynamic bio-research ecosystems in the Southeast, and by expanding our administrative base, we are positioning GeoVax for an accelerated next stage of growth. These facilities will support our broad and advancing pipeline, which includes our promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines.'
Eddie Lai, Director of Business Development at Atlanta Portal Innovations, commented, 'We are incredibly excited for GeoVax to join Portal Atlanta at Science Square Labs. GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations ecosystem that includes 100+ innovative companies utilizing our sites across the country. As an innovation engine, Portal Innovations supports scientific companies including life sciences and biotech in all stages of development in both R&D and administrative capabilities, and GeoVax is a perfect addition to our growth right here in Atlanta.'
The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs. GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation.
GeoVax holds worldwide rights for its technologies and product candidates through a strong IP portfolio. For more information, visit www.geovax.com.
